        Y. Haik 1,2 , R. Sista 1,3 , A. Qablan 1 , CJ. Chen 1 , S. Palanki 1,3 1 Center for Nanomagnetics and Biotechnology, Florida State University, Tallahassee, FL, haik@eng.fsu.edu 2 Department of Mechanical Engineering, United Arab Emirates University, Al Ain, UAE 3 Department of Chemical and Biomedical Engineering, FAMUFSU College of Engineering, Tallahassee, FL  Due to the increasing number of AMI patients accompanied with a difficulty in diagnosing the anomaly, a major push to develop innovative approaches to tackle the recognition of myocardial infarctions has been noticed. Most of these advances utilize immunoassays to decrease the time of acute myocardial infarction (AMI) detection, granting the patient a better chance of survival. This article presents a technique for rapidly isolating cardiac markers from a sample solution. The paper also presents techniques to correlate the concentrations of AMI markers with detectable labels. : AMI, Nanomagnetics, Diagnostics, Detection.   Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the world. The emergency department evaluation of patients with potential acute coronary syndromes has traditionally included initial cardiac marker testing for suspected Acute Myocardial Infarction (AMI) [1]. Because of lack of sensitivity in current measuring methods for AMI half million people in America are mistakenly discharged from ER to have AMI later at home [2]. Currently electrocardiographs (ECG) are used in concert with blood serum protein elevations to diagnose the infarction. It has been shown that the diagnostic sensitivity of an ECG is approximately 50% in determining myocardial damage [3]. The number of individuals who have been discharged from emergency departments provides further evidence of the need for a more efficient method of AMI detection. It has been indicated that approximately 25% of the patients sent home with an acute myocardial infarction had ST elevations that were misjudged or overlooked by the physician [4]. Also, an estimated 80% of the patients admitted to the coronary care unit for suspected acute myocardial infarction are discharged without having this diagnosis confirmed [5, 6]. More importantly, 28% of the 2 million individuals that were not admitted developed AMIs resulting in added injury to the individual and malpractice actions taken against the institution [7]. Today, with increased emphasis in costeffective decisionmaking and rapid treatment, hospitals are in need for the rapid and efficient determination of AMI for patients admitted to the emergency room with acute chest pain. Point of care or "nearpatient" testing allows diagnostic assays to be performed at the site of patient care delivery in locations such as the emergency department or the intensive care unit where treatment decisions are made and care is delivered based on the results of these assays immediately [8]. Several markers result from the cardiac tissue injury. Myoglobin, Creatine Kinase, Fatty AcidBinding Protein (FACB), Troponin, and Glycogen Phosphorylase (AP) are released into the blood stream immediately after the cardiac injury. Recent studies have shown the ability of Myoglobin and Fatty AcidBinding Protein (FABP) as biochemical markers for the early diagnosis of AMI, especially in the first few hours after the onset of the AMI event [9]. Although common, conventional antibodyantigen interaction immunoassays evaluation techniques require laboratory setting to be performed and are not available at the point of care. An ideal marker that could be used to detect myocardial injury would possess a number of characteristics. It must have high protein concentrations within the myocardium, while being present in low concentrations in noncardiac tissue; it also should rapidly be released after cardiac injury, persists in plasma, and allows the development of accurate and rapid assays [10]. Among other cardiac markers, myoglobin is one of the ideal serum cardiac markers that can be used to test the presented assay and fulfills the aforementioned measurement criteria. Myoglobin is a protein which consists of a single polypeptide chain that composed of 153 amino acids and has a molecular mass of 17.8 KD. In the instance of an AMI twice the normal concentration of myoglobin is found within 2 hours and the level peaks within 4 hours. Presently the use of magnetic particles in immunoassays is growing; due in part to their ability to NSTI-Nanotech 2006, www.nsti.org, ISBN 0-9767985-7-3 Vol. 2, 2006 444